octreotide vs repaglinide
PlainMeds reviewed this comparison against our methodology in August 2026. It places FDA and CMS record fields side by side, without recommending either medication.
Side-by-side comparison of octreotide and repaglinide. Data from FDA drug databases (Orange Book, NDC Directory, recalls, shortages) covering 20,000+ approved drugs, plus CMS pricing; see our methodology.
minor Known Drug Interaction
Examples: Antidiabetic agents, ACE inhibitors, angiotensin II receptor blocking agents, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, nonsteroidal anti-inflammatory agents (NSAIDs), pentoxifylline, pramlintide, propoxyphene, salicylates, somatostatin analogs (e.g., octreotide), and sulfonamide antibiotics Drugs That May Decrease the Blood Glucose Lowering Effect of Repaglinide Intervention: Repaglinide dose increases and increased frequency of glucose monitoring may be required when co-administered.
Sandostatin
Prandin
Octreotide is a drug that mimics a natural hormone in your body. It is used to treat certain conditions caused by too much of certain hormones.
Repaglinide (Prandin) helps control blood sugar in adults with type 2 diabetes. It works best when used with diet and exercise.
Octreotide is used to lower growth hormone and insulin-like growth factor-1 in people with acromegaly who haven't responded to other treatments. It also helps manage severe diarrhea and flushing caused by carcinoid tumors. Additionally, it can treat watery diarrhea caused by VIPomas (tumors that release vasoactive intestinal peptide).
Repaglinide is used to lower blood sugar in adults with type 2 diabetes. It should be used along with a healthy diet and regular exercise. This medicine is not for people with type 1 diabetes or diabetic ketoacidosis.
This medicine works by mimicking somatostatin, a natural hormone in your body. It reduces the amount of certain hormones, like growth hormone, that your body makes. By doing this, it helps control the symptoms caused by having too much of these hormones.
Repaglinide helps your pancreas release insulin after you eat. Insulin helps move sugar from your blood into your cells. This lowers your blood sugar levels.
- • Gallbladder problems
- • Slow heart rate
- • Diarrhea
- • Loose stools
- • Nausea
- • Low blood sugar
- • Upper respiratory infection
- • Headache
- • Sinus infection
- • Joint pain
- Diarrhoea 526
- Death 375
- Nausea 345
- Fatigue 305
- Malignant Neoplasm Progression 235
- Hypoglycaemia 765
- Acute Kidney Injury 548
- Drug Interaction 418
- Diarrhoea 365
- Lactic Acidosis 364
Octreotide can cause heart problems, including a higher risk of certain types of heart block. Your doctor may monitor your heart if you receive this drug intravenously. It can also cause gallbladder problems, high or low blood sugar, and thyroid issues. Tell your doctor right away if you notice new or worsening symptoms.
Repaglinide can cause low blood sugar (hypoglycemia). If you skip a meal, skip your dose of repaglinide to avoid low blood sugar. Do not use repaglinide with NPH-insulin. There is no proof that repaglinide lowers your risk of heart problems.
There is limited information about the safety of octreotide during pregnancy. Talk to your doctor if you are pregnant or plan to become pregnant. It is not known if octreotide passes into breast milk, so talk to your doctor about breastfeeding while using this medicine.
Tell your doctor if you are pregnant or plan to become pregnant. Poorly controlled diabetes during pregnancy can harm both the mother and the baby. Repaglinide is not recommended while breastfeeding due to the risk of low blood sugar in the baby.
Also Compare, Nearby Drugs
Compare repaglinide with
How to Read This octreotide vs repaglinide Comparison
octreotide is classified in the Somatostatin Analog drug class, while repaglinide sits within the Meglitinide class. Drugs from different classes work through distinct mechanisms, so a head-to-head comparison illustrates trade-offs rather than equivalence. Both drugs are prescription-only, so a licensed provider must authorize use.
Adverse event totals above are pulled from the FDA's Adverse Event Reporting System (FAERS). For these top-ranked reactions alone, octreotide has 1,786 submissions while repaglinide has 2,460. Those figures reflect cumulative reporting volume, not per-patient risk, so older, widely dispensed drugs typically look worse on count alone. These two drugs have a known minor interaction flagged in FDA labeling, attributed to octreotide can change how repaglinide affects your blood sugar, making it harder to keep your levels steady.. Serious warnings, pregnancy guidance, and contraindications can differ even when indications overlap.
A table cannot represent individual circumstances. Data here is sourced from FDA Structured Product Labels (SPL) and FAERS, both of which update as manufacturers and clinicians submit new information. This registry does not provide medical, treatment, substitution, or medication-change directions for octreotide or repaglinide.
Registry boundary: This comparison displays source-record fields and does not provide individualized medical direction.